Noble Financial Has Bullish Forecast for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at Noble Financial raised their Q1 2026 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a research note issued on Tuesday, March 31st. Noble Financial analyst R. Leboyer now forecasts that the company will earn ($0.45) per share for the quarter, up from their prior forecast of ($0.47). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q2 2026 earnings at ($0.52) EPS, Q4 2026 earnings at $0.87 EPS and FY2026 earnings at $0.85 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its earnings results on Monday, March 30th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.36).

Several other equities analysts also recently weighed in on the stock. Guggenheim reiterated a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th. Finally, Westpark Capital began coverage on Unicycive Therapeutics in a report on Thursday, February 19th. They issued a “buy” rating for the company. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.33.

Unicycive Therapeutics Stock Performance

Shares of UNCY opened at $7.12 on Thursday. Unicycive Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $11.00. The business has a 50-day moving average of $6.67 and a 200 day moving average of $5.78. The firm has a market cap of $179.71 million, a P/E ratio of -3.28 and a beta of 1.81.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UNCY. Vivo Capital LLC grew its holdings in Unicycive Therapeutics by 57.4% in the 3rd quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock worth $7,804,000 after acquiring an additional 652,901 shares during the last quarter. Millennium Management LLC bought a new position in shares of Unicycive Therapeutics during the fourth quarter valued at about $5,856,000. Vanguard Group Inc. boosted its holdings in shares of Unicycive Therapeutics by 8.7% during the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after purchasing an additional 52,925 shares during the period. Cantor Fitzgerald L. P. bought a new stake in shares of Unicycive Therapeutics in the fourth quarter worth about $1,154,000. Finally, Geode Capital Management LLC increased its holdings in Unicycive Therapeutics by 36.2% during the 4th quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock valued at $989,000 after purchasing an additional 45,563 shares during the period. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.